Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
Rhea-AI Summary
Halberd (OTC: HALB) reports significant progress in its partnership with Athena GTX, which recently secured a $2,866,000 final development contract for their Smart Autonomous Critical Care System (S-ACCS). The collaboration focuses on two key technologies for Traumatic Brain Injuries (TBI) and Suicide Ideation treatment.
The partnership has led to two distinct development tracks: Athena's WatchDawg® Pilot Study leading the Suicide Ideation treatment project, and Halberd's TBI mitigation nasal spray development program at Mississippi State University. The company is pursuing FDA clearance for their LDX treatment program through Athena Telemedicine Partnership, (ATP), which combines pharmacy, nutraceuticals, monitoring, and psychological therapies for veteran mental health issues.
Halberd is currently seeking funding for FDA clinical trials, including a 30-50 participant Phase 1 and a 100-150 participant Phase 2 study. The company is also exploring opportunities with indigenous American tribes and pursuing additional government contracts, with two awards pending for the WatchDawg software portal and the Nasal Spray program.
Positive
- Secured $2.866M government contract for S-ACCS development
- Two additional government contract awards pending
- Successfully completed initial animal tests at Mississippi State University
- Filed provisional patent application based on pilot study results
- Expanded market potential identified for commercial applications
Negative
- Facing government funding delays
- Seeking alternative private funding sources
- Longer development timeline expected for TBI nasal spray product
- FDA clearance still pending for key products
News Market Reaction 1 Alert
On the day this news was published, HALB declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
The US Government Granted Athena GTX a
JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal government. Of the two technologies associated with Traumatic Brain Injuries (TBI)/Suicide Ideation for which we chose to pursue government funding, Athena’s success via the WatchDawg® Pilot Study was chosen to lead the Suicide Ideation treatment project, while Halberd, via the successful Mississippi State University initial animal tests, leads the TBI mitigation nasal spray development program.
The website we established to do the hard work on market development and FDA clearance for our LDX adjunct treatment program is indeed now part of the Athena Telemedicine Partnership, LLC (ATP). That partnership involves the pharmacy, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation. This approach is significantly better, has been thoroughly documented as to clinical efficacy, and has permitted the filing of a provisional patent application based on the previous pilot study results.
Finally, we are currently seeking near-term funding to execute the FDA clearance plan for LDX, including both a 30-50 participant Phase 1 clinical trial and then a 100-150 participant Phase 2 study. We are also awaiting key demographic studies with the indigenous American tribes both here in the continental USA and in Alaska. The rates of mental health issues, alcoholism, and suicidal ideation are very large in these demographic areas.
These all are focused on obtaining the required safety and efficacy data for we need to get an FDA clearance via an expedited program this year. In light of government funding delays, we are negotiating with the private funding sector to support our ongoing work.
Our plan for commercialization of our LDN+/LDX PTSD/Suicidal ideation treatment product is to move to compounded pharmacy formulations under the appropriate compounding laws, until FDA clearance for the proprietary LDN+/LDX combined drug is achieved. After finishing a comprehensive government and commercial market assessment, we discovered that the projections for potential commercial applications are significantly higher than originally thought.
Concurrently, Halberd continues to lead the work with Mississippi State University on the TBI therapeutic nasal spray. In addition to pursuing government contracts, we have begun planning for Phase #2 animal studies. This nasal spray technology product is believed to require a longer-term development process, but we believe this product could offer an even greater market potential. We have pending government contract awards in this technology product and have completed critical proposals to support this work. We hope to hear positive response to our petitions shortly.
On the positive side, the Athena GTX team was awarded a
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
| For more information please contact: | |
| William A. Hartman | Mark Darrah, PhD |
| Chairman, CEO, President, Halberd Corp. | CEO Athena GTX |
| w.hartman@halberdcorporation.com | mmdarrah@athenagtx.com |
| support@halberdcorporation.com | www.athenagtx.com/ |
| www.halberdcorporation.com | |
| Twitter:@HalberdC | |
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring – Athena GTX connects patient and provider About - Athena GTX® Inc.
About Halberd Corporation.
Halberd Corporation (OTC PINK: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. Halberd’s policy for responding to individual shareholder questions is to be responsive, while refraining from providing information which relates to or could compromise any information pertaining to trade secrets or that may otherwise compromise our competitive advantages. Simultaneously with such disclosure or potential disclosure, Halberd will make the responsive information public through a tweet, press release or some other form of social media/mass media communication.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2025, Halberd Corporation
FAQ
What is the value of the contract awarded to Athena GTX for the S-ACCS development?
How many participants are planned for HALB's LDX clinical trials?
What are the two main technology tracks in HALB's partnership with Athena GTX?
What services does HALB's Athena Telemedicine Partnership (ATP) combine?
